Biocartis Group NV (BCART.BR)

0.2900 0.0000 (0.00%) At close: 04:35PM CET

Biocartis Group NV

Generaal de Wittelaan 11 B
Mechelen 2800
Belgium
32 1 563 26 00
https://www.biocartis.com

Sector(s): Healthcare
Industry: Diagnostics & Research
Full-time employees: 526

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Piet Houwen	Chief Operating Officer	N/A	N/A	1968
Mr. Roger Moody	Chief Executive Officer	N/A	N/A	N/A
Mr. George A. Cardoza	CFO & Head of Service Delivery	N/A	N/A	1962
Mr. Benoit Devogelaere	Chief Technology Officer	N/A	N/A	1981
Mr. Geert Maertens Ph.D.	Chairman of Scientific Advisory Board & Chief Scientific Officer	N/A	N/A	N/A
Renate Degrave	Head of IR & Corporate Communications	N/A	N/A	N/A
Ms. Susy Spruyt	Head of People & Organization	N/A	N/A	1968
Dr. Erwin Sablon	Head of R&D and Alliance Management	N/A	N/A	1965
Mr. Reginald Van Genechten	Head of Manufacturing & Supply Chain	N/A	N/A	1966
Mr. Erik Vossenaar	Vice President of Business Development	N/A	N/A	1973

Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests, as well as SeptiCyte RAPID, a rapid host-response test. It also provides research products, including MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R mutation assays. The company has a collaboration agreement with Amgen to evaluate Idylla RAS testing as a tool for rapid decentralized testing and/or to accelerate access to RAS biomarker information using Idylla platform and RAS tests; and Bristol-Myers Squibb Company for the registration of diagnostic and use of the Idylla MSI test in connection with immuno-oncology therapies. It also has a license, development, and commercialization agreement with GeneproDx for the development of ThyroidPrint novel genomic test on the Idylla platform; and collaboration with APIS Assay Technologies Ltd. to develop and commercialize breast cancer subtyping test on the Idylla platform. The company was founded in 2007 and is headquartered in Mechelen, Belgium.

Corporate governance

Biocartis Group NV’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.